News
News
Academy
Multimedia
Editorial PodcastsEditorial VideosPeer ExchangeProfiles in Medicine
Conferences
Conference CoverageConference Listing
More
Publications
Pharmaceutical Executive
Partner Perspectives
Resources
Content Engagement HubsE-BooksEventsSponsored PodcastsSponsored VideosWebcastsWhitepapers

Subscribe

  • News
  • Academy
  • Multimedia
  • Conferences
  • Publications
  • Partner Perspectives
  • Resources
  • Subscribe
  • Corporate Communications
    • Press Releases
    • Executive Roundtable
    • Executive Profiles
    • Leadership
  • Direct-to-Consumer
    • Patient Education
    • Healthcare Access
    • Telehealth
  • Emerging Biopharma
    • Partnerships
    • Funding
  • IR Licensing and Partnerships
    • Finance
    • Industry Trends
  • Market Access
    • Patient Access
    • Pricing
    • Strategy
  • Medical Affairs
    • Patient Advocacy
    • Clinical Data
    • Pharmacovigilance
  • Operations
    • Sustainability
    • Technology
    • R&D/Clinical Trials
    • Supply Chain
  • Patient Engagement
    • DE&I
  • Regulatory
    • FDA
    • Legal
    • Global
  • Sales & Marketing
    • Sales Effectiveness
    • Campaigns
    • DTC Marketing
    • Medical Education
Spotlight -
Asembia 2025 |
Sales Effectiveness|
Latest Executive Roundtables
Advertisement

Jeanne Linke Northrop

Advertisement

Articles by Jeanne Linke Northrop

Dave Bearss, PhD, CEO, Halia Therapeutics Image courtesy of Halia Therapeutics

Pushing Boundaries to Revolutionize Chronic Inflammation Therapy

ByJeanne Linke Northrop
June 13th 2024

Novel approaches against chronic inflammation could potentially prevent certain inflammatory diseases and neurological conditions.

Advertisement

Latest Updated Articles

  • Dave Bearss, PhD, CEO, Halia Therapeutics Image courtesy of Halia Therapeutics
    Pushing Boundaries to Revolutionize Chronic Inflammation Therapy

    Published: June 13th 2024 | Updated:



Advertisement
Advertisement

Trending on PharmExec

1

FDA Announces New Plausible Mechanism Pathway

2

Roundup: Ovid Therapeutics and Metagenomi Announce 2025 Third Quarter Results and Leadership Updates

3

Pfizer’s Proven Playbook: Buy, Partner, Scale, Spin-Off, Optimize

4

Pharmaceutical Executive Daily: Dr. Richard Pazdur Appointed as Director CDER

5

Bristol Myers Squibb Expands its Strategic Collaboration with Sarah Cannon Research Institute

  • About
  • Advertise
  • Contact Us
  • Editorial Board
  • Editorial Submission Guidelines
  • Do Not Sell My Personal Information
  • Privacy Policy
  • Terms and Conditions
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

609-716-7777

Brand Logo

© 2025 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us